Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | ANPEP | P15144 | 1/20 | 0.31 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.30 |
| ▸ | ACE | P12821 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL688826 | 1.00 | ATM (0.36) | ATMCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL12362348 | 1.00 | ATM (0.36) | ATMCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL12618449 | 1.00 | ATM (0.36) | ATMCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL13684382 | 1.00 | ATM (0.36) | ATMCHRM2CHRM4CHRM5CHRM1 | |
| Hydrochloric Acid SCHEMBL7326307 | 0.98 | ATM (0.35) | ATMCHRM2CHRM4CHRM5CHRM1 | |
| Hydrochloric Acid SCHEMBL1303237 | 0.98 | ATM (0.35) | ATMCHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL16440622 | 0.84 | CHRM2 (0.36) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL8917152 | 0.84 | CHRM2 (0.36) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL13663762 | 0.82 | MMP2 (0.42) | MMP2ANPEP | |
| SCHEMBL14077854 | 0.82 | MMP2 (0.42) | MMP2ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166660-A1 | KRAS G12C INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2024-05-23 | — | — | US | disclosed |
| US-20230312542-A1 | HYDROXYPYRROLIDINE DERIVATIVE AND MEDICINAL APPLICATION THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-10-05 | — | — | US | disclosed |
| EP-2522356-B1 | BIOACTIVE FRACTION OF PETIVERIA ALLIACEA, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND COMBINATION WITH IMMUNOSTIMULANTS FOR TREATING CANCER | PONTIFICIA UNIV JAVERIANA (CO) | 2018-12-05 | — | — | EP | disclosed |
| US-20150148311-A1 | NON-SYSTEMIC TGR5 AGONISTS | ARDELYX INC (US) | 2015-05-28 | — | — | US | disclosed |
| US-8734863-B2 | Bioactive fraction of Petiveria alliacea, pharmaceutical composition containing same, and combination with immunostimulants for treating cancer | PONTIFICIA UNIVERSIDAD JAVERIANA (CO) | 2014-05-27 | — | — | US | disclosed |
| US-20120294897-A1 | BIOACTIVE FRACTION OF PETIVERIA ALLIACEA, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND COMBINATION WITH IMMUNOSTIMULANTS FOR TREATING CANCER | PONTIFICIA UNIVERSIDSD JAVERIANA (CO) | 2012-11-22 | — | — | US | disclosed |
| EP-2522356-A2 | BIOACTIVE FRACTION OF PETIVERIA ALLIACEA, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND COMBINATION WITH IMMUNOSTIMULANTS FOR TREATING CANCER | Pontificia Universidad Javeriana (CO) | 2012-11-14 | — | — | EP | disclosed |
| WO-2011056244-A1 | ANGINA PECTORIS AND ISCHEMIC HEART DISEASE AND SYNERGISTIC PHYTOCEUTICAL COMPOSITION FOR SAME | OLALDE RANGEL JOSE ANGEL (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20110052718-A1 | Synergistic Phytoceutical Compositions | RANGEL JOSE ANGEL OLALDE | 2011-03-03 | — | — | US | disclosed |
| US-7682616-B2 | Synergistic phytoceutical compositions | OLALDE RANGEL JOSE ANGEL | 2010-03-23 | — | — | US | disclosed |
| US-7682617-B2 | Synergistic phytoceutical compositions | OLALDE RANGEL JOSE ANGEL | 2010-03-23 | — | — | US | disclosed |
| US-7618639-B2 | Synergistic phytoceutical compositions | OLALDE RANGEL JOSE ANGEL | 2009-11-17 | — | — | US | disclosed |
| US-20090196941-A1 | Synergistic Phytoceutical Compositions | OLALDE RANGEL JOSE ANGEL | 2009-08-06 | — | — | US | disclosed |
| US-7553501-B2 | Immune phyto-neutraceutical composition | Olalde Rangel, Jose Angel (US) | 2009-06-30 | — | — | US | disclosed |
| US-20090155377-A1 | Synergistic Phytoceutical Compositions | OLALDE RANGEL JOSE ANGEL | 2009-06-18 | — | — | US | disclosed |
| US-7390512-B2 | Multiple sclerosis synergistic phyto-nutraceutical composition | Olalde Rangel, Jose Angel (US) | 2008-06-24 | — | — | US | disclosed |
| US-20080089946-A1 | Synergistic Phytoceutical Compositions | OLALDE RANGEL JOSE A | 2008-04-17 | — | — | US | disclosed |
| US-20080081046-A1 | MULTIPLE SCLEROSIS SYNERGISTIC PHYTO-NUTRACEUTICAL COMPOSITION | OLALDE JOSE ANGEL | 2008-04-03 | — | — | US | disclosed |
| WO-2007059441-A2 | SYNERGISTIC PHYTOCEUTICAL COMPOSITIONS | OLALDE RANGEL JOSE ANGEL (US) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148311-A1 | NON-SYSTEMIC TGR5 AGONISTS | GLP1R, GPR119, TRHR | ATM 2311/4885CHRM2 147/4885CHRM4 266/4885 |
| US-20240166660-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | ATM 2707/4885CHRM2 4881/4885CHRM4 4882/4885 |
| US-20230312542-A1 | HYDROXYPYRROLIDINE DERIVATIVE AND MEDICINAL APPLICATION THEREOF | VHL, MDM2, NEDD4 | ATM 3074/4885CHRM2 4826/4885CHRM4 4863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.